Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene.
Sign Up to like & getrecommendations! Published in 2019 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2019.01.024
Abstract: BACKGROUND AND AIMS The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del)… read more here.
Keywords: mutation; subjects leu167del; lowering response; leu167del mutation ... See more keywords
The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes"
DOI: 10.1111/dom.12936
Abstract: Albuminuria reduction is essential for renal and cardiovascular protection. We characterized the efficacy of dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on albuminuria. Secondly, we assessed whether the albuminuria‐lowering effect varies among patients, and whether this… read more here.
Keywords: response dapagliflozin; lowering response; albuminuria lowering; dapagliflozin variable ... See more keywords
Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s131487
Abstract: Background Statins are effective agents in the primary and secondary prevention of cardiovascular disease, but treatment response to statins varies among individuals. We analyzed multiple genetic polymorphisms and assessed pharmacokinetic and lipid-lowering responses after atorvastatin… read more here.
Keywords: lowering response; atorvastatin; pharmacokinetics lipid; lipid lowering ... See more keywords